ClinicalTrials.gg
RecruitingNCT05742373Updated Mar 7, 2024

Role of Fasted Exercise on Improving Cardiometabolic Health

An interventional study of Exercise training in the fasted state and Exercise training in the fed state in Cardiovascular Diseases, Diabetes Mellitus, Type 2 and Obesity, sponsored by Manchester Metropolitan University. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-07.

Sponsored by Manchester Metropolitan University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The aim of this randomised control trial is to investigate the role of fasted exercise on cardiometabolic health. Participants will be assigned to one of three conditions, fasted exercise, fed exercise and control (no exercise). Participants in the exercise groups will complete four weeks of moderate intensity cycling exercise, three times per week, either in the fasted or fed state according to their group assignment. Experimental trials involving anthropometric and cardiometabolic disease risk factor measurements as well as metabolic responses to a subsequent meal ingestion following exercise will be compared pre-intervention and post intervention.

Read the detailed description

The aim of this study is to investigate the effect of fasted exercise on cardiometabolic health and the potential mediatory role of sirtuins.

The objectives are to investigate:

  1. The effect of a single bout of fasted exercise on acute metabolic responses following a high fat meal.
  2. The effect of four weeks of fasted exercise training on cardiovascular and metabolic disease risk factors.
  3. The effect of four weeks of fasted exercise training on circulating levels and subcutaneous adipose tissue gene expression of SIRT1, SIRT3 and SIRT6.

A randomised control trial will be conducted with volunteers allocated under the conditions of a) no exercise (control), b) fasted exercise training (FASTEX) and c) fed exercise training (FEDEX). The pre- and post-intervention visits will consist of 50 minutes of cycling at a moderate exercise intensity for both the FASTEX and FEDEX groups. The control group would not perform any exercise. The FASTEX group will perform the exercise in the fasted state, whilst the FEDEX and control groups will be fed a standardised breakfast meal one hour in advance of the exercise period. Following the exercise period, the participants will be fed a high fat meal and metabolic responses to the meal will be measured for four hours. Multiple blood samples will be obtained as well as a sample of subcutaneous adipose (fat) tissue. The FASTEX and FEDEX groups will then complete four weeks of moderate intensity continuous exercise training, either fasted or fed according to their group, on three days per week whilst the control group will maintain their normal sedentary lifestyle. All participants will return to the laboratory for post-intervention testing at the end of the four weeks with the same protocols and measurements as the pre-intervention testing.

02

Conditions studied

  • Cardiovascular Diseases
  • Diabetes Mellitus, Type 2
  • Obesity

Keywords

  • Cardiovascular disease
  • Diabetes Mellitus
  • Obesity
  • Cardiometabolic health
  • Exercise
  • Fasted
  • Sirtuins
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 30 is below the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Manchester Metropolitan University is the lead sponsor of 19 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Non-smokers
  • Physically inactive (partake in no more than one exercise session per week on average)
  • >18.5 kg/m2
  • Healthy as assessed by medical screening questionnaire
  • Prior recipient of local anaesthetic with no known adverse effects, no known or no other health issue that may constrain the administration of lidocaine hydrochloride
  • Free from musculoskeletal injury and able to perform cycling exercise
  • Capacity to give

Exclusion criteria

Exclusion Criteria:

  • Regular exerciser
  • \< 18.5 kg/m2
  • Pregnant
  • Allergy or intolerances to test meal products/ingredients (such as wheat or dairy products).
  • Recent major body weight change (+/- 3 kg in the past month)
  • Known to Lidocaine Hydrochloride
  • Cardiovascular disease - complete heart block or hypovolaemia
  • Adam's-Stokes Syndrome
  • Wolff-Parkinson-White Syndrome
  • Porphyria
  • Epilepsy
  • Myasthenia Gravis
  • Other chronic medical condition or diagnosis including respiratory (eg asthma), endocrine, cardiovascular, neuromuscular disorders.
  • Taking medications or receiving treatment that may constrain the administration of lidocaine or local anaesthesia.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Fasted exercise

    Exercise training in the fasted state

    Other: Exercise training in the fasted state

  • Active comparator
    Fed exercise

    Exercise training in the fed state

    Other: Exercise training in the fed state

  • No intervention
    Control

    No exercise training

Interventions

  • OtherExercise training in the fasted state

    Four weeks of moderate intensity cycling exercise, three times a week without eating breakfast meal

  • OtherExercise training in the fed state

    Four weeks of moderate intensity cycling exercise, three times a week, after eating breakfast meal

06

What researchers measure

Primary outcomes

  1. Changes in circulating concentrations of key metabolic markers following a high fat lunch meal

    Serum concentrations of clinical chemistry blood analytes (glucose, triglycerides, cholesterol)

    Time frame: 9 blood samples collected at pre-meal ingestion then every 30 min after ingestion for four hours

  2. Changes in circulating concentrations of key metabolic markers during the experimental trial day

    Serum concentrations of clinical chemistry blood analytes (glucose, triglycerides, cholesterol)

    Time frame: 12 blood samples collected at 0 (baseline), 75 (pre-exercise), 125 (immediately post-exercise), 155 min (pre-meal ingestion) then every 30 min after ingestion for four hours

  3. Area under the circulating concentration versus time curve (AUC) of key metabolic markers following a high fat lunch meal

    Total responses of clinical chemistry blood analytes (glucose, triglycerides, cholesterol)

    Time frame: 4.5 hours

  4. Changes in cardiovascular and metabolic disease biochemistry risk factors

    Fasted serum concentrations of clinical chemistry blood analytes (glucose, blood lipids, inflammatory markers)

    Time frame: 4 weeks (pre and post intervention)

  5. Changes in cardiovascular disease physiological risk factors

    Systolic and diastolic blood pressure and calculation of mean arterial pressure using systolic and diastolic values

    Time frame: 4 weeks (pre and post intervention)

  6. Changes in concentration of sirtuin molecules

    Serum concentrations of sirtuins

    Time frame: 4 weeks (pre and post intervention)

  7. Changes in sirtuin molecule gene expression

    Adipose tissue gene expression of sirtuins

    Time frame: 4 weeks (pre and post intervention)

  8. Changes in sirtuin molecule tissue expression

    Adipose tissue expression and cellular localisation of sirtuins

    Time frame: 4 weeks (pre and post intervention)

Secondary outcomes

  1. Changes in cardiovascular and metabolic disease anthropometric risk factors

    Waist circumference, hip circumference and waist:hip ratio

    Time frame: 4 weeks (pre and post intervention)

  2. Change in body composition

    Body fat percentage measured using bioelectrical impedance analysis

    Time frame: 4 weeks (pre and post intervention)

  3. Change in body mass

    Body mass in kilograms

    Time frame: 4 weeks (pre and post intervention)

  4. Change in substrate oxidation during the experimental trial day

    Carbohydrate and fat oxidation through indirect calorimetry

    Time frame: 17 measurements at 0 (baseline), 15 (post-breakfast meal period), 45 (30 min post-breakfast meal period), 75 (pre-exercise), every 10 min during exercise, 155 (pre-meal ingestion), then every 30 min for four hours.

  5. Heart rate response to exercise

    Heart rate during exercise in the experimental trial using telemetry

    Time frame: At rest before exercise then every 5 min during 50 min cycle exercise

  6. Perceived exertion

    Rating of perceived exertion of exercise in the experimental trial using Borg scale

    Time frame: Every 5 min during 50 min cycle exercise

  7. Change in physical activity levels

    Physical activity energy expenditure during the intervention period

    Time frame: Daily for 4 weeks

  8. Change in physical activity duration

    Amount of time spent performing physical activity at different intensities (low, moderate, high) during the intervention period

    Time frame: Daily for 4 weeks

  9. Change in energy intake

    Energy intake using weighed food diary record during the intervention period

    Time frame: Daily for 4 weeks

  10. Change in dietary nutritional intake

    Macronutrient (carbohydrate, fat, protein) composition of food intake using weighed food diary record during the intervention period

    Time frame: Daily for 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Manchester Metropolitan University
    Manchester, Greater Manchester M1 5GD, United Kingdom
    Recruiting
    • Adora Yau, PhD · Contacta.yau@mmu.ac.uk · +44(0)1612475504
    • Gethin Evans, PhD · Contactgethin.evans@mmu.ac.uk · +44(0)1612471208
    • Adora Yau, PhD · Principal investigator
    • Gethin Evans, PhD · Sub investigator
    • Ria Weston, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Planned communication of group results at a scientific conference. Planned publication in a scientific peer reviewed journal. Participant level data is not expected to be available as this complies with the conditions of the ethical approval granted for this study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Apr 2025, 25 months after the start.

Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 25 months is close to that.

Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2023
First posted
Feb 24, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Apr 2025
CompletionEst.
May 2025
Last update
Mar 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05742373
Lead sponsor
Manchester Metropolitan University
Collaborators
European Society for Clinical Nutrition and Metabolism
Responsible party
Adora Yau (Senior Lecturer, Manchester Metropolitan University) — Principal investigator
First posted
Feb 24, 2023
Start date
Mar 1, 2023
Primary completion
Apr 2025 (estimated)
Completion
May 2025 (estimated)
Last update
Mar 7, 2024

Study contacts

Adora Yau, PhD
Contact
a.yau@mmu.ac.uk
+44(0)1612475504
Gethin Evans, PhD
Contact
gethin.evans@mmu.ac.uk
+44(0)1612471208
Adora Yau, PhD
principal investigator · Manchester Metropolitan University
Gethin Evans, PhD
study director · Manchester Metropolitan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion